Multiple Myeloma PBMC

Multiple Myeloma PBMC for Tumour Immunology Research

Human Multiple Myeloma PBMC products are sourced from IRB-consented donors clinically diagnosed with multiple myeloma, processed within 24 hours of collection and cryopreserved in CryoStor® CS10 to preserve viability and function. These peripheral blood mononuclear cells enable study of immune evasion, effector-cell dysfunction and treatment resistance in a plasma-cell malignancy, and are available in cell counts from 5 million to 2 billion.

Why Multiple Myeloma PBMC for Tumour Immunology Research

Multiple myeloma is a neoplastic disorder of terminally differentiated plasma cells. Clonal plasma cells accumulate in the bone marrow and secrete a monoclonal immunoglobulin or free light chain, producing bone disease, renal impairment, anaemia and hypercalcaemia. It is a cancer, not an autoimmune disease, and its immunology is that of a tumour that both suppresses and is targeted by the host immune system.

• Plasma-cell lineage antigens — CD38, BCMA, SLAMF7 and GPRC5D define the malignant compartment and are the antigens behind the current wave of antibody, bispecific and CAR-T therapeutics.
• T-cell dysfunction and exhaustion — repeated antigen exposure and a suppressive marrow microenvironment drive inhibitory receptor expression and reduced effector capacity, which can be characterised directly in donor PBMCs.
• Immunosuppressive cell populations — regulatory T cells and myeloid-derived suppressor cells expand in myeloma and blunt anti-tumour responses.
• NK cell effector function — NK cells mediate antibody-dependent cellular cytotoxicity, the mechanism underlying anti-CD38 antibody therapy, and their function in disease-state donors differs from that of healthy cells.
• Circulating plasma cells and clonal detection — a subset of donors carries measurable circulating clonal plasma cells, supporting minimal-residual-disease and clonality workflows on peripheral blood.
• Cellular specimen advantage — because PBMCs are viable nucleated cells, flow cytometry, cytotoxicity assays, redirected-killing potency assays, single-cell transcriptomics and TCR repertoire work are all available; none of these are possible in a plasma or serum product.

Donor Stratification Available

• Disease phase — newly diagnosed, on-treatment, in remission, and relapsed or refractory donors
• Monoclonal protein class — IgG, IgA and light-chain-only disease, subject to documentation
• Precursor and related conditions — MGUS and smouldering myeloma donors as comparators where available
• Treatment exposure — proteasome inhibitor, immunomodulatory drug, anti-CD38 antibody, and post-autologous-transplant donors
• Cytogenetic risk category and demographics — where documented, plus age, sex assigned at birth and race/ethnicity
• Matched healthy controls available, drawn on the same protocol and matched for age, sex and ethnicity

Product Features

• Research Use Only (RUO), cryopreserved PBMCs
• Clinically confirmed multiple myeloma donors
• Available in cell counts ranging from 5 million to 2 billion
• Processed within 24 hours of collection
• Stored using CryoStor® CS10 freezing media
• IRB-approved protocols and electronic informed consent
• Screen LeukoLot™ available prior to bulk orders

De-identified Donor Data

• Verified multiple myeloma diagnosis
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported allergies and infectious disease history
• Disease phase and prior treatment context reported per lot where captured
• Additional multiple myeloma-specific data available upon request

Applications

• BCMA, GPRC5D and SLAMF7-directed bispecific and CAR-T potency assays
• Anti-CD38 antibody-dependent cellular cytotoxicity and NK effector function studies
• T-cell exhaustion and effector dysfunction immunophenotyping
• Regulatory T cell and myeloid-derived suppressor cell characterisation
• Autologous effector-cell sourcing for redirected-killing assay development
• Circulating clonal plasma cell detection and minimal-residual-disease workflow development
• Single-cell transcriptomic and proteomic profiling of the myeloma immune compartment
• Drug screening, resistance modelling and biomarker discovery in myeloma pathophysiology

Other Multiple Myeloma Specimen Types

• Multiple Myeloma Plasma
• Multiple Myeloma Serum
• Multiple Myeloma Whole Blood

Compliance and Quality Assurance

• IRB-approved collections and protocols
• 21 CFR Part 11-compliant e-consent system
• HIPAA-compliant donor data protection

Ordering & Customization

Multiple Myeloma PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. To compare collection formats or check wider availability, visit our human PBMCs page.